EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Stem cell-derived gametes: what to expect when expecting their clinical introduction

Ilse J de Bruin iD, Merel M Spaander iD, Simone Harmsen iD, Rosanne Edelenbosch iD, M Corrette Ploem iD, Nina Dartée, Madalena Cardoso Vaz Santos, Mathangi Lakshmipathi, Callista L Mulder iD, Ans M M van Pelt iD, Willy M Baarends iD, Susana M Chuva de Sousa Lopes iD und 4 weitere

Human Reproduction · 2025

DOI: 10.1093/humrep/deaf123 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Human Reproduction, 2025. Verfasst von Ilse J de Bruin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Developmental Biology, Erasmus MC, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Germ Cells, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Organization for Health Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stem cell-derived (SCD)-gametes derived from induced or autologous (i.e. patient-specific) cells may help mitigate human fertility problems caused by physiological or social factors in the (near) future. While this technology is still in its infancy, recent advancements with SCD-gametes generated from mouse pluripotent stem cells have led some researchers to expect—and investors to anticipate—the clinical introduction of human gametes derived from induced pluripotent stem cells (iPSCD-gametes) within two decades. However, it remains to be investigated how realistic these expectations are, and how they would balance against careful consideration of technical, ethical, legal, and societal aspects, including—but not limited to—safety and effectiveness. This mini-review aims to encourage that investigation by providing a brief overview of the state-of-the-art and highlighting the breadth of issues involved in the potential clinical introduction of human iPSCD-gametes. These issues emerge before (Stage 1), during (Stage 2), and after (Stage 3) clinical trials, and are discussed in that order. Issues discussed in the context of Stage 1 suggest that gathering the evidence required to preclinically assess the safety of human iPSCD-gametes will be time-consuming and require parallel experiments with sensitive research materials. Issues discussed in the context of Stage 2 suggest that it might take several years for human iPSCD-gametes to transition through distinct clinical trial phases, and that inevitable (and unforeseeable) variations in the quality of human iPSCD-gametes are likely to further slow this down. Finally, issues discussed in the context of Stage 3 suggest that offering human iPSCD-gametes clinically will require addressing questions of accountability and monitoring, some of which might be difficult to formalize by law. Combined, these findings suggest that a responsible clinical introduction of human iPSCD-gametes may take considerably longer than expected, underscoring the importance of transdisciplinary collaborations with a broad range of stakeholders to make well-informed and well-considered choices about their development and application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Germ CellsInduced Pluripotent Stem CellsHumansAnimalsFemaleReproductive Techniques, AssistedMaleClinical Trials as Topic

Stichwörter der Autor:innen

in vitro gametogenesisassisted reproductive technologiesclinical applicationethicshumaninduced pluripotent stem cellslawsocietystem cell-derived gametes

Autor:innen und Institutionen

  • Department of Developmental Biology, Erasmus MC, Rotterdam, The Netherlands.
  • Department of Health Law, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Ethics, Law & Humanities, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • Rathenau Institute, The Hague, The Netherlands.
  • Reproductive Biology Laboratory, Center for Reproductive Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Amsterdam Reproduction and Development Research Institute, Amsterdam, The Netherlands.

ORCID-Profile: Ilse J de Bruin, Merel M Spaander, Simone Harmsen, Rosanne Edelenbosch, M Corrette Ploem, Callista L Mulder, Ans M M van Pelt, Willy M Baarends, Susana M Chuva de Sousa Lopes, Guido M W R de Wert, Seppe Segers, Geert Hamer, Ana M Pereira Daoud

Förderung

  • Dutch Organization for Health Research and Development

Zitieren

APA

de Bruin, I. J., Spaander, M. M., Harmsen, S., Edelenbosch, R., Ploem, M. C., Dartée, N., Cardoso Vaz Santos, M., Lakshmipathi, M., Mulder, C. L., van Pelt, A. M. M., Baarends, W. M., Chuva de Sousa Lopes, S. M., de Wert, G. M. W. R., Segers, S., Hamer, G., & Pereira Daoud, A. M. (2025). Stem cell-derived gametes: what to expect when expecting their clinical introduction. Human Reproduction. https://doi.org/10.1093/humrep/deaf123

Vancouver

de Bruin IJ, Spaander MM, Harmsen S, Edelenbosch R, Ploem MC, Dartée N, et al. Stem cell-derived gametes: what to expect when expecting their clinical introduction. Human Reproduction. 2025. doi:10.1093/humrep/deaf123

BibTeX
@article{deBruin2025,
  author = {de Bruin, Ilse J and Spaander, Merel M and Harmsen, Simone and Edelenbosch, Rosanne and Ploem, M Corrette and Dartée, Nina and Cardoso Vaz Santos, Madalena and Lakshmipathi, Mathangi and Mulder, Callista L and van Pelt, Ans M M and Baarends, Willy M and Chuva de Sousa Lopes, Susana M and de Wert, Guido M W R and Segers, Seppe and Hamer, Geert and Pereira Daoud, Ana M},
  title = {Stem cell-derived gametes: what to expect when expecting their clinical introduction},
  journal = {Human Reproduction},
  year = {2025},
  doi = {10.1093/humrep/deaf123}
}
Kostenlos starten →